Provided is an organic metal complex having a structure represented by the following general formula (1):

ML.sub.mL.sub.n(1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML.sub.m represents a structure represented by the following general formula (2):

##STR00001##

and a partial structure ML.sub.n represents a structure including a monovalent bidentate ligand.

Provided is an organic metal complex having a structure represented by the following general formula (1):

ML.sub.mL.sub.n(1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML.sub.m represents a structure represented by the following general formula (2):

##STR00001##

and a partial structure ML.sub.n represents a structure including a monovalent bidentate ligand.

Provided is an organic metal complex having a structure represented by the following general formula (1):

ML.sub.mL.sub.n(1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML.sub.m represents a structure represented by the following general formula (2):

##STR00001##

and a partial structure ML.sub.n represents a structure including a monovalent bidentate ligand.

The present disclosure relates to a process for the halogenation of hydrocarbon. In accordance with the process of the present disclosure a hydrocarbon and a halogen is introduced in a reaction vessel. Light having wavelength in the range of 390 to 780 nm is then passed into the reaction vessel for a time period of 2 to 12 hrs. to obtain a halogenated hydrocarbon. The hydrocarbon is agitated before or after the introduction of the halogen in to the reaction vessel.

The present disclosure relates to a process for the halogenation of hydrocarbon. In accordance with the process of the present disclosure a hydrocarbon and a halogen is introduced in a reaction vessel. Light having wavelength in the range of 390 to 780 nm is then passed into the reaction vessel for a time period of 2 to 12 hrs. to obtain a halogenated hydrocarbon. The hydrocarbon is agitated before or after the introduction of the halogen in to the reaction vessel.

The present disclosure relates to a process for the halogenation of hydrocarbon. In accordance with the process of the present disclosure a hydrocarbon and a halogen is introduced in a reaction vessel. Light having wavelength in the range of 390 to 780 nm is then passed into the reaction vessel for a time period of 2 to 12 hrs. to obtain a halogenated hydrocarbon. The hydrocarbon is agitated before or after the introduction of the halogen in to the reaction vessel.

The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##